Antithrombotic Cancer Associated Thrombosis: It May Change
Received Date: Dec 20, 2018 / Accepted Date: Dec 25, 2018 / Published Date: Dec 29, 2018
Active treatment of acute venous thromboembolism without active bleeding is primarily based on the administration of LMWH, according to international guidelines. However, recent studies have provided data on direct oral anticoagulants that offer interesting new perspectives concerning efficacy in the prevention of recurrent VTE and the safety of these drugs in this particular patient population.
Keywords: VTE; Venous thromboembolism; Rivaroxaban
Citation: Fontanella A, Campanini M, Dentali F, Gussoni G, Manfellotto D, et al. (2018) Antithrombotic Cancer Associated Thrombosis: It May Change. J Blood Lymph S1: 007. Doi: 10.4172/2165-7831.S1-007
Copyright: © 2018 Fontanella A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 731
- [From(publication date): 0-0 - Dec 07, 2019]
- Breakdown by view type
- HTML page views: 690
- PDF downloads: 41